{"nctId":"NCT00263575","briefTitle":"Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients","startDateStruct":{"date":"2005-12"},"conditions":["Pain","Cancer"],"count":139,"armGroups":[{"label":"sublingual fentanyl tablet","type":"EXPERIMENTAL","interventionNames":["Drug: EN3267"]}],"interventions":[{"name":"EN3267","otherNames":["Fentanyl"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males or females 17 years of age or older.\n* Stable cancer-related pain.\n* Are receiving a stable, fixed-schedule oral opioid regimen equivalent to 60 to 1000 mg of oral morphine per day or transdermal fentanyl therapy equivalent to 50 to 300 Âµg/h, and are on a stable dose of opioid medication for relief of breakthrough pain.\n* Experiencing 1-4 episodes of breakthrough pain per day.\n* Meet the criteria defined in the Eastern Cooperative Oncology Group (ECOG) Performance Status for Grade 0, 1, or 2.\n\nExclusion Criteria:\n\n* Have previously been exposed to EN3267.\n* Are pregnant or lactating.\n* Have uncontrolled or rapidly escalating pain.\n* Have any clinically significant condition that would, in the investigator's opinion, preclude participation in the study or compromise data collection. These conditions may include cardiopulmonary disease, and/or neurologic/psychologic conditions.\n* Are scheduled to take MAOIs (monoamine oxidase inhibitors) during the study.\n* Are scheduled to receive anti-neoplastic therapy that, in the investigator's opinion, will influence assessment of breakthrough pain.\n* Are scheduled to receive an investigational drug other than EN3267 during the course of the study.\n* Have hypersensitivity, allergy or contraindication to fentanyl.\n* Have significant prior history of substance abuse or alcohol abuse.\n* Would have difficulty complying with the protocol, as assessed by the investigator.\n* Are unable to read, write, or comprehend the English language in order to complete diaries.","healthyVolunteers":false,"sex":"ALL","minimumAge":"17 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Evaluate the Long-term Safety and Effectiveness of EN3267","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"87","spread":null},{"groupId":"OG002","value":"116","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":46,"n":139},"commonTop":["Nausea","Fatigue","Vomiting","Dehydration","Edema peripheral"]}}}